• Drug Discovery technologies (including Genomics and Pharmainformatics)
  
  
• New Chemical Entity (NCE)
  
  
• Improved Chemical Entity (ICE)
  
  
• DDS and new formulation technology
  
  
• Investment and Information
  
  

Its wholly owned subsidiary, MindGenix Inc., in Albany, NY facilitates drug discovery in Alzheimerﾕs diseases by utilizing a platform, APP/PS1 mouse model.

A fully integrated drug discovery company applying its advanced, proprietary tools in biology, chemistry and informatics to rapidly discover and develop new classes of drugs. Its initial focus is on the discovery of novel antibacterial agents.

Flunet, a second generation of Relenza, influenza treating drug. Anti-virus drugs for Renovirus (common cold) and SRV

LAX-101 (E-EPA) for treatment of Huntingtonﾕs disease and depression - Phase II in US and Europe.

Imagent for ultrasound imaging agent.

Soltara (norastemizole) for allergy Other improved chemical entities.

Gene Therapy using adenovirus vector to deliver genes. BioBypass, angiogen for cardiovascular disease, APEDF for ophthalmology and TNFerade for oncology.

SC-103 (Ascorbic-GLA) for treatment of diabetic neuropathy. Nippon Chemiphar (Japan)
NC-1800, a CNS acting drug for pollakiuria and Urinary incontinence.
NC-1900, an Arginine-vasopressin for improvement of the memory and cognitive function.
NC-2100, a thiazolidinedione derivative for treatment of type II diabetes.
NC-1200, a glutamate blocking activity to improve vertigo and dizziness of subjective symptom.

ATX-S10, a photodynamic therapy agent for treatment of cancers.
ATN-10, a tumor imaging agent with technetium-99m.
PAD-S31, a photodynamic therapy agent for animal use.

FYK-1258f, an opioid peptide.
F81 1144b, MMP inhibitor for asthma.

Maruho Co., Ltd., Osaka,
Wyeth Lederle Japan, Ltd., Tokyo
L.T.T. Bio-Pharma Co., Ltd., Tokyo, Japan
Morishta Jintan Co., Ltd., Osaka, Japan
Q.P.Corporation, Tokyo, Japan
Toyobo Co., Ltd., Otsu, Shiga, japan

KEA Partners (USA)